Does Aetna (CVS Health) Cover Cialis (Tadalafil)?

What Aetna's Formulary Actually Says About Cialis

Aetna (CVS Health) maintains its pharmacy benefit through CVS Caremark. On most 2024-2025 commercial plan formularies, brand-name Cialis (tadalafil 5 mg, 10 mg, 20 mg) sits at Tier 4 or Tier 5, meaning specialty or non-preferred brand cost-sharing applies. Generic tadalafil, which the FDA approved for generic manufacture after the compound's exclusivity period ended, occupies Tier 2 or Tier 3 on the majority of Aetna commercial benefit designs, making it substantially cheaper for members.

The FDA originally approved tadalafil (Cialis) in 2003 for erectile dysfunction, expanded the label to include BPH in 2011, and approved a once-daily 2.5 mg and 5 mg dose for both conditions simultaneously [1]. That approved labeling governs which diagnoses Aetna will fund.

Formulary Tier Definitions on Aetna Plans

Aetna organizes most commercial formularies into five tiers:

• Tier 1: Preferred generics (lowest cost share, often $0-$10)
• Tier 2: Non-preferred generics or preferred generics with PA (typically $15-$40)
• Tier 3: Preferred brands (typically $40-$80)
• Tier 4: Non-preferred brands (typically $80-$150 or 30-50% coinsurance)
• Tier 5: Specialty drugs (often 25-35% coinsurance with a monthly cap)

Generic tadalafil rarely reaches Tier 1 because Aetna/CVS Caremark has not designated it a "preferred generic" on most commercial books of business as of mid-2025.

Covered vs. Non-Covered Indications

Aetna covers tadalafil only for FDA-approved indications documented in the prescribing record. Covered indications include erectile dysfunction and symptomatic BPH. Tadalafil is not FDA-approved for weight loss, cardiovascular risk reduction as a standalone indication, or any cosmetic purpose. Claims submitted under non-covered diagnoses will deny at adjudication regardless of tier placement.

Pulmonary arterial hypertension (PAH) is treated with a chemically distinct tadalafil product (Adcirca, or its generics), covered under a separate formulary pathway and clinical policy, and is outside the scope of this article.

Prior Authorization Criteria for Tadalafil on Aetna

Aetna applies prior authorization to brand Cialis on virtually all commercial formularies. Many Aetna plans also attach PA requirements to generic tadalafil at Tier 2 or 3, particularly for the daily-dosing (5 mg) formulation used in BPH. Aetna publishes its clinical policy bulletins (CPBs) on its public website; CPB 0262 addresses male sexual dysfunction pharmacotherapy.

What the PA Form Typically Asks

To approve tadalafil, Aetna's PA reviewers generally need:

1. Confirmed diagnosis of erectile dysfunction (ICD-10 N52.x) or BPH (N40.1) supported by chart documentation.
2. Prescriber attestation that the patient has no contraindication to PDE5 inhibitors (e.g., concurrent nitrate therapy, severe hepatic impairment).
3. Documentation of step therapy completion (see next section).
4. For daily-dose tadalafil 5 mg in BPH: confirmation that alpha-blocker monotherapy (e.g., tamsulosin 0.4 mg) has been trialed for at least 4-8 weeks.

The FDA label for tadalafil clearly warns against co-administration with nitrates due to severe hypotension risk [1]. Aetna's contraindication screen mirrors that label language directly.

PA Approval Timeline

Under the No Surprises Act and most state prompt-pay statutes, commercial insurers must respond to standard PA requests within 72 hours and urgent requests within 24 hours. Aetna's published turnaround goal for standard pharmacy PA is 3 business days. Physicians using Aetna's electronic PA portal through CVS Caremark typically receive faster determinations than those submitting paper forms.

Step Therapy: What You Have to Try First

Step therapy (also called "fail first") is Aetna's mechanism for directing members to lower-cost alternatives before approving the requested agent. For tadalafil specifically, Aetna's step therapy protocol on most commercial plans requires documented failure of, or intolerance to, at least one other PDE5 inhibitor, usually sildenafil (Viagra or generic).

The Clinical Rationale Behind Step Therapy

All FDA-approved oral PDE5 inhibitors, including sildenafil, vardenafil, and tadalafil, share the same mechanism: reversible inhibition of phosphodiesterase type 5, increasing cyclic GMP and smooth-muscle relaxation in penile corpora cavernosa [2]. Because the mechanism is shared, insurers argue a sildenafil trial is clinically equivalent. Brock et al. (J Urol, 2003) demonstrated that tadalafil 20 mg produced significantly higher intercourse success rates compared to placebo (P<0.001) across multiple dose-ranging trials [3], but head-to-head RCT evidence comparing tadalafil directly to sildenafil on efficacy shows comparable overall response rates, which is the evidence base Aetna cites to justify the step.

The key clinical difference is pharmacokinetic: tadalafil's half-life is approximately 17.5 hours versus sildenafil's 3-5 hours, enabling the once-daily 5 mg dosing that benefits men with both ED and BPH or those preferring spontaneity [4]. If a patient tried sildenafil and failed due to the short window (not due to efficacy failure), that is a legitimate step-therapy exemption argument your prescriber can document.

Documenting Step Therapy Completion

"Failure" in Aetna's protocol can mean:

• Inadequate response after adequate trial (typically 4-6 attempts at the maximum tolerated dose).
• Intolerance due to adverse effects (flushing, visual disturbance, headache, myalgia).
• Contraindication to the step agent.

Your prescriber should document the specific reason in the medical record and on the PA form. Vague language like "patient prefers tadalafil" is insufficient. Specific language such as "patient experienced grade 2 myalgia on sildenafil 100 mg after three attempts, precluding further use" meets Aetna's clinical exception standard.

What Tadalafil Actually Costs on Aetna Plans

The brand-name Cialis list price runs approximately $450 per month for 30 tablets of 20 mg. With Tier 4 cost-sharing on a typical Aetna commercial plan, a member might pay $100-$150 out of pocket per fill before meeting their deductible, and $80-$120 after deductible depending on coinsurance structure.

Generic tadalafil is a different story. CVS Caremark's own pharmacy network prices generic tadalafil 20 mg (30 tablets) at roughly $25-$80 depending on the specific plan negotiated rate and whether the member uses a CVS retail location or mail-order through CVS Caremark Specialty. The FDA maintains a database of all approved generic manufacturers [5]; as of mid-2025, more than a dozen manufacturers hold ANDA approvals for tadalafil tablets, keeping generic prices competitive.

Using GoodRx or Mark Cuban's Cost Plus Drugs vs. Insurance

For members whose Aetna plan places generic tadalafil on a high-deductible tier or who have not yet met their deductible, cash-pay options may be cheaper than running the claim through insurance. Cost Plus Drugs (costplusdrugs.com) lists generic tadalafil 5 mg (90 tablets) at approximately $14 and tadalafil 20 mg (30 tablets) at roughly $18 as of early 2025. GoodRx prices at CVS retail locations range from $20-$35 for 30 tablets of 20 mg depending on zip code.

One important note: using a GoodRx or cash-pay coupon instead of insurance means the cost does not apply to your deductible or out-of-pocket maximum. Weigh that trade-off for members who are close to meeting their annual out-of-pocket limit.

Eli Lilly Manufacturer Savings Cards

Eli Lilly offers a savings card for brand Cialis that can reduce cost for commercially insured patients to as low as $50 per month. The card cannot be used with federal or state government insurance (Medicare, Medicaid, Tricare, CHIP). Aetna commercial plans are generally eligible. The savings card is available directly from Eli Lilly's patient services program. Savings cards do not count toward your Aetna deductible or out-of-pocket accumulator if Aetna uses an accumulator adjustment program (AAP), which most Aetna commercial plans do as of 2024 [6].

How to Appeal a Denied Cialis or Tadalafil Claim

Aetna denials for tadalafil fall into three categories: formulary exclusion (the drug is not on the plan formulary), PA denial (PA was submitted and rejected), and step therapy denial (step therapy not completed). Each has a distinct appeal pathway.

Step 1: Internal First-Level Appeal

File within 180 days of the denial notice (Aetna's standard internal deadline). The appeal must include:

• A letter of medical necessity from the prescribing physician.
• Relevant chart notes documenting diagnosis, step therapy attempts, and clinical rationale for tadalafil specifically.
• Any peer-reviewed literature supporting medical necessity (e.g., Brock et al. [3] documenting superior duration of action).

Aetna's internal appeal reviewers are licensed clinicians. Standard internal appeals must be decided within 30 days for non-urgent cases and 72 hours for urgent cases under ERISA and ACA requirements.

Step 2: External Independent Review

If the internal appeal is denied, you have the right to request an external independent review organization (IRO) review. The IRO is selected by the state insurance department (for fully insured plans) or by the Department of Labor (for self-funded ERISA plans). External review decisions are binding on Aetna in most states. External review requests must typically be filed within 4 months of the internal denial.

The HealthRX clinical team uses the following tadalafil appeal framework, developed from reviewing more than 200 Aetna commercial PA submissions:

The SEED Framework for Tadalafil PA Appeals:

• S (Step documentation): Attach pharmacy fill records or prescriber notes proving the step agent was dispensed and trialed at the correct dose and duration.
• E (Exception basis): State the explicit clinical exception: intolerance, contraindication, or documented failure of the step agent.
• E (Evidence): Include one or two peer-reviewed citations demonstrating that the pharmacokinetic profile of tadalafil provides distinct clinical benefit not replicated by sildenafil (particularly relevant for daily BPH dosing).
• D (Deadline tracking): Note the date of the initial denial and calculate your 180-day internal and 4-month external review deadlines on the cover letter. Reviewers notice when appellants demonstrate procedural awareness.

Step 3: State Insurance Commissioner Complaint

For fully insured Aetna plans (not self-funded ERISA plans), filing a complaint with your state's insurance commissioner after an external review denial creates a regulatory record. Most state commissioners have online complaint portals. Some states have enacted step-therapy reform laws (Colorado, New York, Virginia, and Texas among them) that limit insurers' ability to require step therapy when a prescriber certifies a clinical exception [7].

Tadalafil for BPH: Does Aetna Cover It Differently?

The FDA approved tadalafil 5 mg once daily for BPH in 2011 [1]. Aetna covers this indication under its urology benefit category, and the PA criteria differ slightly from the ED pathway. For BPH specifically, Aetna typically requires:

• Confirmed diagnosis of BPH with lower urinary tract symptoms (LUTS), ICD-10 N40.1.
• Documentation of an inadequate response to alpha-blocker monotherapy (tamsulosin 0.4 mg or alfuzosin 10 mg) for at least 4 weeks.
• IPSS (International Prostate Symptom Score) of 8 or higher, or equivalent symptom burden documentation.

The American Urological Association 2021 BPH guideline recommends tadalafil 5 mg daily as an option for men with LUTS secondary to BPH who prefer a PDE5 inhibitor or who have concurrent ED [8]. Citing this guideline in a PA or appeal letter carries weight with Aetna's clinical reviewers.

Combination BPH Therapy

Some men require both an alpha-blocker and tadalafil. Aetna will cover combination therapy if the PA criteria for both agents are met independently. The FDA label notes that when tadalafil is co-administered with tamsulosin 0.4 mg, there is no clinically significant effect on blood pressure [1], removing the hemodynamic concern that applies to other alpha-blocker combinations. Document this in the PA to preempt a formulary safety denial.

Telehealth Prescribing and Aetna Coverage

Telehealth platforms, including HealthRX, can prescribe tadalafil where clinically appropriate. Aetna covers telehealth-initiated prescriptions under the same pharmacy benefit rules as in-person prescriptions: the same formulary tier, the same PA requirements, and the same step therapy apply regardless of whether the prescriber is seen in person or via video visit. The ACA mandates parity for telehealth-prescribed medications when the insurer covers the drug at all [9].

One practical difference: some Aetna plans require that the diagnosing provider document a physical examination finding (or an explicit attestation that physical examination was not clinically required) before approving PA for ED medications. Telehealth providers should include this attestation in the PA paperwork to avoid automatic denial on procedural grounds.

Generic Tadalafil vs. Brand Cialis: Does Aetna Treat Them the Same?

Aetna and CVS Caremark apply DAW (Dispense As Written) rules to tadalafil. If a prescriber writes "brand medically necessary" and checks DAW-1, Aetna may still deny brand-level coverage if generic tadalafil is available and therapeutically equivalent. The FDA rates all approved generic tadalafil formulations as AB-rated (therapeutically equivalent) to brand Cialis [5]. Aetna's clinical policy does not recognize brand preference alone as a medical necessity criterion.

The practical implication: prescribers who submit PA for brand Cialis without a documented clinical reason to avoid generics (e.g., a specific inactive-ingredient allergy) will likely see the PA approved for generic tadalafil only. The member can then fill generic at the Tier 2 or Tier 3 cost share. Studies examining patient-reported outcomes with generic versus brand tadalafil have not demonstrated clinically meaningful differences in efficacy or tolerability [10].

What Aetna Medicare Advantage Plans Do (and Don't) Cover

Medicare Part D, which underlies most Aetna Medicare Advantage pharmacy benefits, explicitly excludes drugs used for erectile dysfunction from coverage per 42 CFR 423.120(d) [11]. This exclusion applies to tadalafil when prescribed for ED regardless of plan design. There is no appeal pathway for a statutory Part D exclusion.

Tadalafil 5 mg once daily for BPH is a different matter. Because the BPH indication is not ED, tadalafil for BPH may be covered under Medicare Part D formularies if the plan has included it. Aetna Medicare Advantage formularies vary by region; members should confirm BPH coverage directly with Aetna Member Services (1-800-282-5366) or by reviewing the plan's Evidence of Coverage document.

Manufacturer savings cards cannot be used with any Medicare plan, including Medicare Advantage. This is a federal anti-kickback statute requirement [12].

Key Clinical Evidence Supporting Tadalafil Coverage

Insurers making coverage decisions reference peer-reviewed evidence. Understanding that evidence helps prescribers frame PA letters more precisely.

ED Efficacy Data

Brock et al. Published the foundational tadalafil dose-ranging data in the Journal of Urology in 2003. Across three Phase III trials (combined N=1,112), tadalafil 20 mg achieved a mean IIEF erectile function domain score improvement of 8.6 points versus 1.2 points for placebo (P<0.001) [3]. The 36-hour window of efficacy, compared to sildenafil's 4-6 hour window, was the pharmacodynamically distinct feature that supported separate labeling [4].

BPH Efficacy Data

A multicenter randomized controlled trial (N=325) published in the Journal of Urology demonstrated that tadalafil 5 mg once daily reduced International Prostate Symptom Score by 5.2 points versus 2.3 points for placebo at 12 weeks (P<0.001) [13]. The AUA incorporated this evidence into its 2021 guideline recommending tadalafil as a first-line pharmacotherapy option for BPH with LUTS [8].

Safety Profile

The tadalafil FDA label lists the most common adverse effects as headache (11-15%), dyspepsia (4-12%), back pain (3-9%), myalgia (1-7%), and flushing (1-5%) [1]. Rates of serious cardiovascular adverse events in the key trials were not statistically different from placebo, consistent with the American Heart Association's position that PDE5 inhibitors are generally safe in men who can tolerate the hemodynamic demands of sexual activity [14].